OrthoRegenTec Limited

The global anti-aging market exceeds US$216 billion, with regenerative therapies poised for exponential growth at a critical juncture.  This project’s technological front addresses unmet needs in the field of longevity medicine, offering personalised solutions for age-associated decline in the body. Strategic partnerships with pharmaceutical industry leaders and a streamlined clinical trial pathway pave the way for breakthrough innovations to disrupt traditional healthcare models. The project pioneers a transformative approach to regenerative medicine by combining novel chimeric antigen receptor mesenchymal stem cells (CAR-MSCs) and adeno-associated virus (AAV) gene therapy to address a plethora of age-related degenerative diseases. By engineering MSCs to express CARs that target urokinase-type plasminogen activator receptors, it also enables precise targeting of senescent cells, while AAV-mediated silent information regulator 1, 6 and 7 replenishment restores youthful cellular function. This dual strategy rejuvenates aged tissues, enhances regeneration, and mitigates chronic inflammation. Such scientific breakthroughs can be extended to the development of controlled virus release hydrogel, thereby spearheading new paths for anti-aging vaccine and CAR-MSCs cytotherapy development.

 
Key Team Member(s)
Prof. WEN Chun-yi (Department of Biomedical Engineering)